Carl Zeiss Meditec AG, Jena
Carl Zeiss AG, Oberkochen
The aforementioned companies and hereby Carl Zeiss Meditec AG as PIE (public interest entity) are each inviting tenders for the engagement to audit their annual financial statements in accordance with the provisions of local law and for the audit of the consolidated financial statements in accordance with IFRS for the financial year 2022/23 (October 1st, 2022 - September 30th, 2023). The call for tenders also covers various other audit services for the named companies (e.g. the review of separated non-financial statements on group level for the Carl Zeiss AG and the audit of the dependent company report for Carl Zeiss Meditec AG and Carl Zeiss AG and the audit of certain financial statements of other companies included in the consolidated financial statements of Carl Zeiss Meditec AG and Carl Zeiss AG respectively).
Auditors (m/f/d) / audit firms can register their interest in participating by 12.00 a.m. CEST on May 22th, 2020, at the central contact address
After this date minimum qualification criteria will be applied to selected applicants out of the timely registered ones to go forward to the next stage. At this point of time also confidentiality agreements and further tender documents will be distributed to these remaining auditors (m/f/d) / audit firms.
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX and SDax of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 3,232 employees (as of 30 September 2019) worldwide, the Group generated revenue of €1,459.3m in fiscal year 2018/19 (as of 30 September).
The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.
For further information visit: www.zeiss.com/med